The Medical Advisor

Lung cancer remains one of the most challenging and deadly malignancies worldwide, with limited effective treatment options for advanced stages despite advances in targeted therapies and immunotherapies. Patients with metastatic or treatment-resistant disease often face poor prognoses and unmet clinical needs, prompting exploration of novel and adjunctive therapeutic approaches. For patients with actionable mutations identified through molecular profiling, targeted therapies are the preferred treatment approach. In particular, for "PD-L1 High Non-Small Cell Lung Cancer", single-agent immunotherapy may be more effective and better tolerated than chemotherapy in selected patients. The preference for targeted treatments reflects their demonstrated efficacy in improving outcomes in these molecularly defined subgroups, underscoring the importance of comprehensive genomic profiling in guiding personalized therapy decisions. However, targeted agents are only applicable to small pati...